Skip to content

Myriad Genetics MYGN Convertible Preferred Stock Outstanding Shares

Convertible Preferred Stock Outstanding Shares at other companies

Labcorp Holdings logo
Labcorp HoldingsLH
Veracyte logo
VeracyteVCYT
Guardant Health logo
Guardant HealthGH
GeneDx Holdings logo
GeneDx HoldingsWGS
Castle Biosciences logo
Castle BiosciencesCSTL
Azenta logo
AzentaAZTA

Other financials

Income statement

See full
Revenue$200.4M+2.3%
Gross profit$137.6M+2.5%
Operating income-$30.7M-5.9%
Net income-$34.1M-34,000%
EPS (diluted)-$0.36

Balance sheet

See full
Cash & equivalents$126.0M+24.8%
Total debt$211.5M+34.2%
Total equity$337.4M-52.1%
Total assets$673.7M-33.0%

Cash flow

See full
Operating cash flow-$15.7M+3.7%
CapEx$18.8M+181%
Free cash flow-$19.7M+65.1%

Valuation

See full
Market cap$512.85M+13.1%
Enterprise value$598.35M+17.3%
P/S0.6×+0.1×

Profitability

See full
Gross margin70%0.0pp
Operating margin-46.9%-88.3pp
Net margin-48.2%-72.9pp
FCF margin-17%

Returns & leverage

See full
Return on equity-76.7%-98.4pp
Debt / equity0.6×+0.4×
Current ratio2.4×+0.5×

Where this comes from

Reported directly by Myriad Genetics in its filing.

Tagged under the XBRL concept us-gaap:PreferredStockSharesOutstanding.

The official record: Myriad Genetics’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Myriad Genetics's convertible preferred stock outstanding shares.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Myriad Genetics's convertible preferred stock outstanding shares?
Myriad Genetics (MYGN) reported convertible preferred stock outstanding shares of 0 in Q1 2026.